Publication Date:
2010-11-19
Description:
Abstract 1266 Allogeneic hematopoietic stem cell transplantation (HSCT) of older or comorbid patients has become feasible due to new protocols for reduced toxicity/intensity conditioning. Particularly using fludarabine, BCNU and melphalan (FBM) as preparative regimen confers reduced toxicity with substantial anti-leukemic activity. Nevertheless, chronic Graft-versus-Host disease (cGvHD) of the lung remains a serious non infectious, late onset pulmonary complication, contributing to treatment related morbidity and mortality. Since the clinical entity of pulmonary cGvHD after reduced toxicity/intensity conditioning has not yet been well characterized, we performed a retrospective analysis of patients, who were transplanted after FBM conditioning at the University Hospital Freiburg between 1998 and 2007, were alive at least 100 days after HSCT and have pulmonary function tests available. 259 patients were enrolled in this study (median age at PBSCT of 61 years (range 24–76)) with a median follow up of 33 months (range 4–133). All patients received conditioning with fludarabin (4-5 × 30 mg/m2), BCNU (or carmustin, patients〉 55 years: 2×150 mg/m2, 55 years 1×110mg/m2, 10 % of the initial value of FEV1, in ratio of RV/TLC 〉45 %, in values of MEF50
Print ISSN:
0006-4971
Electronic ISSN:
1528-0020
Topics:
Biology
,
Medicine
Permalink